Physician profile
Ryan Wilcox
NPI 1033344767
$8,536.92
in general payments reported to CMS, 2019-2025
11 companies · $8,331 in 2025
The $8,331 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $29.10 · 2024: $13.47 · 2025: $8,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,500 · Travel and Lodging: $1,294 · Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,500.00 |
| Travel and Lodging | $1,294.23 |
| Food and Beverage | $549.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $8,193.98 | 2024-2025 | Yescarta |
| Janssen Biotech, INC. | $150.00 | 2025 | Rybrevant, Carvykti |
| Amgen INC. | $33.29 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $32.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.45 | 2019-2020 | |
| Clovis Oncology, INC. | $20.36 | 2019 | |
| Shire North American Group INC | $17.40 | 2019 | |
| Puma Biotechnology, INC. | $17.22 | 2019 | |
| Heron Therapeutics, INC. | $16.77 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.50 | 2019 | |
| Genentech USA, INC. | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.